StreetInsider.com News Articles

Adagio Medical explores strategic options, cuts workforce

Wed, 23 Sep 2026 08:00:54 -0400

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has initiated a formal process to explore strategic alternatives, including a possible acquisition, merger, or business combination, according to a press release from the company.

The board of directors completed a review of the company's business and resources before launching the process. In connection with the decision, Adagio Medical is implementing a workforce reduction to align its cost structure with its prioritized programs. No timetable has been set for the evaluation, and the company said it does not intend to disclose further developments unless required.

As of June 30, 2026, the company held approximately $7.7 million

Adagio Medical explores strategic options, cuts workforce

Wed, 23 Sep 2026 08:00:54 -0400

As of June 30, 2026, the company held approximately $7.7 million

Adagio Medical explores strategic options, cuts workforce

Wed, 23 Sep 2026 08:00:54 -0400

As of June 30, 2026, the company held approximately $7.7 million

Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value

Wed, 23 Sep 2026 08:00:00 -0400

Company Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Board of Directors has completed a comprehensive review of the Company's business, programs, resources and capabilities and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. In connection with this decision, the Company is implementing a reduction in workforce to align its

Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value

Wed, 23 Sep 2026 08:00:00 -0400

Company Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options

Adagio Medical treats first patient in vCLAS Ultra IDE study

Wed, 16 Sep 2026 08:02:11 -0400

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has treated the first patient in its investigational device exemption (IDE) study evaluating the next-generation vCLAS Ultra Ultra-Low Temperature Ablation system for sustained monomorphic ventricular tachycardia (SMVT), according to a company press release.

The procedure was performed by Dr. Roderick Tung at Banner – University Medical Center Phoenix. The patient had non-ischemic cardiomyopathy and recurrent ventricular tachycardia following a prior catheter ablation. The target site was a thick anatomic area beneath the mitral valve, an area the company described as presenting challenges in catheter reach and lesion depth.

"The catheter reached a sub-valvular substrate just under

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Wed, 16 Sep 2026 08:00:00 -0400

Enrollment Underway Across Multiple Sites as Study Advances Faster, Improved ULTA Catheter for the Broadest Population of VT Patients

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation (“ULTA”) Ventricular Ablation System. The study is designed to support a Premarket Approval (“PMA”) supplement to the Company’s PMA for its first generation vCLAS system, which is presently under review by

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Wed, 16 Sep 2026 08:00:00 -0400

Enrollment Underway Across Multiple Sites as Study Advances Faster, Improved ULTA Catheter for the Broadest Population of VT Patients

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation (“ULTA”) Ventricular Ablation System. The study is designed to support a Premarket Approval (“PMA”) supplement to the Company’s PMA for its first generation vCLAS system, which is presently under review by

Teleflex adds former Medtronic cardiovascular chief to its board

Tue, 08 Sep 2026 06:31:09 -0400